Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses. D'Alise AM, Leoni G, Cotugno G, Siani L, et al. Clin Cancer Res 2024;30:2412-2423.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

D'Alise AM, Leoni G, Cotugno G, Siani L, et al. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses. Clin Cancer Res 2024;30:2412-2423.
PMID: 38506710